Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

Silvio Danese; Gionata Fiorino; Pierre Michetti

doi:10.1016/j.crohns.2014.06.007

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

Silvio Danese, Gionata Fiorino, Pierre Michetti

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

Original language	English
Pages (from-to)	1548-1550
Number of pages	3
Journal	Journal of Crohn's & colitis
Volume	8
Issue number	11
DOIs	https://doi.org/10.1016/j.crohns.2014.06.007
Publication status	Published - 2014

Keywords

Biosimilar
ECCO
Inflammatory bowel disease
Monoclonal

ASJC Scopus subject areas

Gastroenterology
Medicine(all)

Access to Document

10.1016/j.crohns.2014.06.007

Cite this

@article{eec83c244200488ca6da179ac49113b8,

title = "Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization",

abstract = "Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.",

keywords = "Biosimilar, ECCO, Inflammatory bowel disease, Monoclonal",

author = "Silvio Danese and Gionata Fiorino and Pierre Michetti",

year = "2014",

doi = "10.1016/j.crohns.2014.06.007",

language = "English",

volume = "8",

pages = "1548--1550",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Viewpoint

T2 - Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

AU - Danese, Silvio

AU - Fiorino, Gionata

AU - Michetti, Pierre

PY - 2014

Y1 - 2014

N2 - Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

AB - Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

KW - Biosimilar

KW - ECCO

KW - Inflammatory bowel disease

KW - Monoclonal

UR - http://www.scopus.com/inward/record.url?scp=84929610400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929610400&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2014.06.007

DO - 10.1016/j.crohns.2014.06.007

M3 - Article

C2 - 25008477

AN - SCOPUS:84929610400

VL - 8

SP - 1548

EP - 1550

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 11

ER -

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this